Type I insulin-like growth factor receptor antisense strategies in experimental breast cancer

We addressed the effect of targeting type I insulin-like growth factor receptor (IGF-IR), with antisense strategies in vivo growth of breast cancer cells. We used C4HD tumors from an experimental model of hormonal carcinogenesis in which medroxyprogesterone acetate induced mammary adenocarcinomas in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salatino, M., Schillaci, R., Proietti, C.J., Carnevale, R., Charreau, E.H., Elizalde, P.V.
Formato:	JOUR
Materias:	Antisense strategies Breast cancer IGF-IR antisense oligodeoxynucleotide epidermal growth factor receptor 2 insulin receptor substrate 1 medroxyprogesterone acetate messenger RNA mitogen activated protein kinase oligodeoxynucleotide phosphorothioate progesterone receptor protein kinase B somatomedin C receptor animal cell animal experiment animal model article breast adenocarcinoma breast cancer cancer cell cancer growth cancer inhibition dose response drug targeting enzyme activation hormonal carcinogenesis in vivo culture mouse nonhuman protein expression protein phosphorylation protein targeting Adenocarcinoma Animal Diseases Animals Dose-Response Relationship, Drug Female Mammary Neoplasms, Experimental Medroxyprogesterone Mice Mice, Inbred BALB C Oligodeoxyribonucleotides, Antisense Receptor, IGF Type 1 Receptors, Somatomedin RNA, Messenger Tumor Cells, Cultured
Acceso en línea:	http://hdl.handle.net/20.500.12110/paper_00257680_v64_n2_p129_Salatino
Aporte de:	Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) de Universidad de Buenos Aires

id	todo:paper_00257680_v64_n2_p129_Salatino
record_format	dspace
spelling	todo:paper_00257680_v64_n2_p129_Salatino2023-10-03T14:36:39Z Type I insulin-like growth factor receptor antisense strategies in experimental breast cancer Salatino, M. Schillaci, R. Proietti, C.J. Carnevale, R. Charreau, E.H. Elizalde, P.V. Antisense strategies Breast cancer IGF-IR antisense oligodeoxynucleotide epidermal growth factor receptor 2 insulin receptor substrate 1 medroxyprogesterone acetate messenger RNA mitogen activated protein kinase oligodeoxynucleotide phosphorothioate progesterone receptor protein kinase B somatomedin C receptor animal cell animal experiment animal model article breast adenocarcinoma breast cancer cancer cell cancer growth cancer inhibition dose response drug targeting enzyme activation hormonal carcinogenesis in vivo culture mouse nonhuman protein expression protein phosphorylation protein targeting Adenocarcinoma Animal Diseases Animals Dose-Response Relationship, Drug Female Mammary Neoplasms, Experimental Medroxyprogesterone Mice Mice, Inbred BALB C Oligodeoxyribonucleotides, Antisense Receptor, IGF Type 1 Receptors, Somatomedin RNA, Messenger Tumor Cells, Cultured We addressed the effect of targeting type I insulin-like growth factor receptor (IGF-IR), with antisense strategies in vivo growth of breast cancer cells. We used C4HD tumors from an experimental model of hormonal carcinogenesis in which medroxyprogesterone acetate induced mammary adenocarcinomas in Balb/c mice. Intratumor or systemic administration of phosphorothiolated antisense oligodeoxynucleotides (AS[S]ODN) to IGF-IR mRNA resulted in a significant inhibition of C4HD tumor growth. The antitumor effect was specific since inhibition of tumor growth was dose-dependent and no effect was observed in mice treated with sense S[S]ODN. Tumors from AS[S]ODN-treated mice showed a decrease in IGF-IR expression and in insulin receptor substrate-1 tyrosine phosphorylation. Activation of PI-3K/Akt, p42/p44 MAPK and ErbB-2 was abolished in tumors treated with AS[S]ODN. Progesterone receptor expression or activity remained invariable. This is the first demonstration that breast cancer growth can be inhibited by direct in vivo administration of IGF-IR AS[S]ODN. JOUR info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/2.5/ar http://hdl.handle.net/20.500.12110/paper_00257680_v64_n2_p129_Salatino
institution	Universidad de Buenos Aires
institution_str	I-28
repository_str	R-134
collection	Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA)
topic	Antisense strategies Breast cancer IGF-IR antisense oligodeoxynucleotide epidermal growth factor receptor 2 insulin receptor substrate 1 medroxyprogesterone acetate messenger RNA mitogen activated protein kinase oligodeoxynucleotide phosphorothioate progesterone receptor protein kinase B somatomedin C receptor animal cell animal experiment animal model article breast adenocarcinoma breast cancer cancer cell cancer growth cancer inhibition dose response drug targeting enzyme activation hormonal carcinogenesis in vivo culture mouse nonhuman protein expression protein phosphorylation protein targeting Adenocarcinoma Animal Diseases Animals Dose-Response Relationship, Drug Female Mammary Neoplasms, Experimental Medroxyprogesterone Mice Mice, Inbred BALB C Oligodeoxyribonucleotides, Antisense Receptor, IGF Type 1 Receptors, Somatomedin RNA, Messenger Tumor Cells, Cultured
spellingShingle	Antisense strategies Breast cancer IGF-IR antisense oligodeoxynucleotide epidermal growth factor receptor 2 insulin receptor substrate 1 medroxyprogesterone acetate messenger RNA mitogen activated protein kinase oligodeoxynucleotide phosphorothioate progesterone receptor protein kinase B somatomedin C receptor animal cell animal experiment animal model article breast adenocarcinoma breast cancer cancer cell cancer growth cancer inhibition dose response drug targeting enzyme activation hormonal carcinogenesis in vivo culture mouse nonhuman protein expression protein phosphorylation protein targeting Adenocarcinoma Animal Diseases Animals Dose-Response Relationship, Drug Female Mammary Neoplasms, Experimental Medroxyprogesterone Mice Mice, Inbred BALB C Oligodeoxyribonucleotides, Antisense Receptor, IGF Type 1 Receptors, Somatomedin RNA, Messenger Tumor Cells, Cultured Salatino, M. Schillaci, R. Proietti, C.J. Carnevale, R. Charreau, E.H. Elizalde, P.V. Type I insulin-like growth factor receptor antisense strategies in experimental breast cancer
topic_facet	Antisense strategies Breast cancer IGF-IR antisense oligodeoxynucleotide epidermal growth factor receptor 2 insulin receptor substrate 1 medroxyprogesterone acetate messenger RNA mitogen activated protein kinase oligodeoxynucleotide phosphorothioate progesterone receptor protein kinase B somatomedin C receptor animal cell animal experiment animal model article breast adenocarcinoma breast cancer cancer cell cancer growth cancer inhibition dose response drug targeting enzyme activation hormonal carcinogenesis in vivo culture mouse nonhuman protein expression protein phosphorylation protein targeting Adenocarcinoma Animal Diseases Animals Dose-Response Relationship, Drug Female Mammary Neoplasms, Experimental Medroxyprogesterone Mice Mice, Inbred BALB C Oligodeoxyribonucleotides, Antisense Receptor, IGF Type 1 Receptors, Somatomedin RNA, Messenger Tumor Cells, Cultured
description	We addressed the effect of targeting type I insulin-like growth factor receptor (IGF-IR), with antisense strategies in vivo growth of breast cancer cells. We used C4HD tumors from an experimental model of hormonal carcinogenesis in which medroxyprogesterone acetate induced mammary adenocarcinomas in Balb/c mice. Intratumor or systemic administration of phosphorothiolated antisense oligodeoxynucleotides (AS[S]ODN) to IGF-IR mRNA resulted in a significant inhibition of C4HD tumor growth. The antitumor effect was specific since inhibition of tumor growth was dose-dependent and no effect was observed in mice treated with sense S[S]ODN. Tumors from AS[S]ODN-treated mice showed a decrease in IGF-IR expression and in insulin receptor substrate-1 tyrosine phosphorylation. Activation of PI-3K/Akt, p42/p44 MAPK and ErbB-2 was abolished in tumors treated with AS[S]ODN. Progesterone receptor expression or activity remained invariable. This is the first demonstration that breast cancer growth can be inhibited by direct in vivo administration of IGF-IR AS[S]ODN.
format	JOUR
author	Salatino, M. Schillaci, R. Proietti, C.J. Carnevale, R. Charreau, E.H. Elizalde, P.V.
author_facet	Salatino, M. Schillaci, R. Proietti, C.J. Carnevale, R. Charreau, E.H. Elizalde, P.V.
author_sort	Salatino, M.
title	Type I insulin-like growth factor receptor antisense strategies in experimental breast cancer
title_short	Type I insulin-like growth factor receptor antisense strategies in experimental breast cancer
title_full	Type I insulin-like growth factor receptor antisense strategies in experimental breast cancer
title_fullStr	Type I insulin-like growth factor receptor antisense strategies in experimental breast cancer
title_full_unstemmed	Type I insulin-like growth factor receptor antisense strategies in experimental breast cancer
title_sort	type i insulin-like growth factor receptor antisense strategies in experimental breast cancer
url	http://hdl.handle.net/20.500.12110/paper_00257680_v64_n2_p129_Salatino
work_keys_str_mv	AT salatinom typeiinsulinlikegrowthfactorreceptorantisensestrategiesinexperimentalbreastcancer AT schillacir typeiinsulinlikegrowthfactorreceptorantisensestrategiesinexperimentalbreastcancer AT proietticj typeiinsulinlikegrowthfactorreceptorantisensestrategiesinexperimentalbreastcancer AT carnevaler typeiinsulinlikegrowthfactorreceptorantisensestrategiesinexperimentalbreastcancer AT charreaueh typeiinsulinlikegrowthfactorreceptorantisensestrategiesinexperimentalbreastcancer AT elizaldepv typeiinsulinlikegrowthfactorreceptorantisensestrategiesinexperimentalbreastcancer
_version_	1807321595065139200

Type I insulin-like growth factor receptor antisense strategies in experimental breast cancer

Ejemplares similares